Broker’s call: Emcure Pharma (Buy)

Pune-based Emcure Pharmaceuticals is a diversified pharmaceutical company that focuses on developing, manufacturing, and marketing a wide range of products in both domestic and international markets. The company's strong domestic presence includes a significant position in chronic and acute therapies, leadership in women's health, a substantial injectables franchise, and a unique front-end platform called Zuventus.

Emcure has identified multiple low-risk growth opportunities through strategic in-licensing partnerships with global innovators. These partnerships allow the company to access established products and emerging therapy areas without significant R&D investments. The potential growth areas for Emcure include GLP-1, MASH, ophthalmics, dermatology, and consumer health, which provide additional optionality beyond its core portfolio.

On the international front, Emcure has established a robust front-end capability through a well-executed acquisition strategy in Canada and Europe. Simultaneously, the company maintains a vertically integrated supply chain in India. Emcure boasts a large and diverse product pipeline, strong positions in complex generics, and differentiated opportunities such as Semaglutide, Liposomal Amphotericin B, and Lenacapavir. These factors contribute to medium-term growth visibility for the company.

Considering Emcure's diversified domestic franchise, scalable international platforms, proven M&A execution, and multiple complex-product opportunities, the analyst values the company at ₹2,305 per share, based on a 30x FY28E EPS of ₹76.8.